Lien H-C, Lu Y-S, Cheng A-L, Chang W-C, Jeng Y-M, Kuo Y-H, Huang C-S, Chang K-J, Yao Y-T
Department of Pathology, National Taiwan University, College of Medicine, Taipei, Taiwan.
J Pathol. 2006 Jul;209(3):317-27. doi: 10.1002/path.1982.
Glucocorticoid receptor (GR) is a steroid hormone receptor that has been shown to play important roles in mammary development and differentiation, and has been implicated in breast tumourigenesis, but its precise biological significance in mammary pathophysiology remains unclear. In order to generate a comprehensive expression profile for GR in normal versus neoplastic breast tissues, GR expression was investigated in situ in 400 human breast tissue samples, comprising normal tissue and a range of benign, pre-invasive, and invasive lesions, using immunohistochemical assays. The novel expression of GR in myoepithelium, not observed in luminal epithelium, not only demonstrates expression patterns exclusive to the alpha form of oestrogen receptor and progesterone receptor and suggests distinctive functions between GR and these two important steroid hormone receptors in the breast, but may also indicate unique physiological and perhaps pathological roles for the myoepithelium in mediating the effects of glucocorticoid hormones in the breast. The strong expression of GR in metaplastic carcinomas (94.4%) and malignant phyllodes tumours (92.3%) suggests a pathogenetic role for GR, and implies that targeting GR in these tumours may have potential therapeutic application. However, studies on the roles of GR in mammary carcinogenesis should be interpreted with great caution, based on the lack of GR expression in cancer cells in the great majority (98.2%) of non-metaplastic carcinomas, which has gone unnoticed in previous studies. This marked discrepancy warrants a re-examination of the biological roles of GR in the pathophysiology of breast malignancy. The lack of methylation in the promoter region of the GR gene in all 118 non-metaplastic carcinomas, as demonstrated by methylation-specific PCR and bisulphite DNA sequencing analysis, indicates that methylation is less likely to play a role in the reduction of GR expression in non-metaplastic carcinoma of the breast.
糖皮质激素受体(GR)是一种类固醇激素受体,已被证明在乳腺发育和分化中起重要作用,并与乳腺肿瘤发生有关,但其在乳腺病理生理学中的精确生物学意义仍不清楚。为了生成GR在正常与肿瘤性乳腺组织中的全面表达谱,使用免疫组织化学分析方法,对400例人类乳腺组织样本(包括正常组织以及一系列良性、癌前浸润性和浸润性病变)中的GR表达进行了原位研究。GR在肌上皮中的新表达在管腔上皮中未观察到,这不仅证明了雌激素受体和孕激素受体α形式所特有的表达模式,并提示了GR与这两种重要类固醇激素受体在乳腺中的不同功能,还可能表明肌上皮在介导糖皮质激素对乳腺的作用方面具有独特的生理甚至病理作用。GR在化生癌(94.4%)和恶性叶状肿瘤(92.3%)中的强表达提示了GR的致病作用,并意味着在这些肿瘤中靶向GR可能具有潜在的治疗应用。然而,鉴于在绝大多数(98.2%)非化生癌的癌细胞中缺乏GR表达,而这一点在以往研究中未被注意到,因此对GR在乳腺癌发生中作用的研究应谨慎解读。甲基化特异性PCR和亚硫酸氢盐DNA测序分析表明,在所有118例非化生癌中GR基因启动子区域均未发生甲基化,这表明甲基化不太可能在乳腺非化生癌中GR表达降低中起作用。